CROMA
Croma-Pharma GmbH, founded in 1976 by pharmacists Karin and Gerhard Prinz, is a globally recognized leader in the field of minimally invasive aesthetics. Headquartered in Leobendorf, Austria, Croma specializes in the development and production of high-quality hyaluronic acid syringes and a comprehensive range of aesthetic products. The company's portfolio includes botulinum toxin, hyaluronic acid fillers, lifting threads, biostimulators, and advanced skincare solutions. With a robust presence in over 80 markets worldwide, including the US, Canada, China, and Australia, Croma operates 13 subsidiaries across Europe and Brazil, and collaborates with 60 exclusive export partners. Their innovative products, such as the EXO|E Revitalizing Serum, demonstrate their commitment to combining science with luxury, ensuring effective and safe treatments for their customers. Croma also engages in contract manufacturing for orthopaedics and ophthalmology, further diversifying their expertise and market reach. As a family-owned business, Croma continues to support healthcare professionals by providing cutting-edge, minimally invasive aesthetic solutions that help patients achieve their best possible appearance.
CROMA Introduction
CROMA develops and distributes a complete range of hyaluronic acid fillers. The company produce Saypha fillers which are Hyaluronic acid based injectables. It is developed to treat a wide range of cosmetic indications and has proven to correct wrinkles, folds and scars, replenish facial volume, augment the lips and also hydrate and rejuvenate the skin. CROMA sells nearly six million hyaluronic acid syringes (injectables) annually through affiliates and a network of strategic partnerships and distributors in more than 70 countries. Production takes place exclusively at the company headquarters in Leobendorf near Vienna, Austria. Founded in 1976 by pharmacist Gerhard Prinz, CROMA is now managed by his sons Martin and Andreas Prinz.